Insmed (NASDAQ:INSM) Given New $193.00 Price Target at TD Cowen

Insmed (NASDAQ:INSM) had its price objective raised by TD Cowen from $154.00 to $193.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. Citigroup raised Insmed to a “buy” rating in a research note on Tuesday, June 10th. HC Wainwright increased their target price on Insmed from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, June 11th. Morgan Stanley increased their target price on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, Jefferies Financial Group increased their target price on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. Nineteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $145.69.

Insmed Trading Up 3.7%

Shares of INSM stock opened at $152.80 on Thursday. The company’s fifty day simple moving average is $131.39 and its two-hundred day simple moving average is $98.41. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed has a 1 year low of $60.40 and a 1 year high of $152.85. The stock has a market capitalization of $32.30 billion, a price-to-earnings ratio of -26.76 and a beta of 1.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 6,865 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the sale, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $30,035,841.60. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the sale, the insider owned 36,461 shares of the company’s stock, valued at approximately $5,303,252.45. This represents a 67.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 277,332 shares of company stock valued at $33,842,327 in the last quarter. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently made changes to their positions in the business. M&T Bank Corp increased its stake in shares of Insmed by 4.7% during the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 147 shares in the last quarter. First Horizon Advisors Inc. increased its stake in shares of Insmed by 24.8% during the second quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 186 shares in the last quarter. ORG Partners LLC increased its stake in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares in the last quarter. Cullen Frost Bankers Inc. increased its stake in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Insmed by 6.5% during the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 228 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.